PetMed Express, Inc. (PETS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PetMed Express, Inc. (PETS) trades at $1.96 with AI Score 28/100 (Grade F). PetMed Express, Inc. operates as a pet pharmacy in the United States, marketing prescription and non-prescription pet medications and health products. Market cap: $41.89M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for PETS: PETS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PETS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PETS: 1/1 perspectives are bearish.
How is this calculated? →PetMed Express, Inc. (PETS) Healthcare & Pipeline Overview
PetMed Express, Inc. (PETS) is a pet pharmacy in the U.S., offering prescription and non-prescription medications, health products, and supplies for pets. The company distributes its products through online and offline channels, facing competition in a growing but fragmented pet medication market.
What Is the Investment Thesis for PETS?
PetMed Express, Inc. faces challenges given its negative profit margin of -35.5% and a market capitalization of $41.89M. The company's gross margin stands at 29.0%. Growth catalysts include expanding its online presence and leveraging its established brand recognition. However, increasing competition from both online and brick-and-mortar retailers, along with evolving consumer preferences, pose significant risks. Investors should closely monitor the company's ability to improve profitability and adapt to the changing market dynamics in the pet medication industry.
Based on FMP financials and quantitative analysis
PETS Key Highlights
- Market Cap: $0.05B, reflecting its small size within the pet pharmaceutical industry.
- Profit Margin: -35.5%, indicating significant challenges in achieving profitability.
- Gross Margin: 29.0%, showing the percentage of revenue exceeding the cost of goods sold.
- Beta: 0.78, suggesting lower volatility compared to the overall market.
- Dividend Yield: None, indicating that the company does not currently distribute dividends to shareholders.
Who Are PETS's Competitors?
PETS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHWY Chewy, Inc. | $21.50 | +3.14% | $8.91B | 64 |
| AMZN Amazon.com, Inc. | $244.70 | +0.84% | $2.63T | 69 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PETS's Key Strengths?
- Established brand recognition.
- Direct-to-consumer distribution.
- Wide range of products.
- Convenient online platform.
What Are PETS's Weaknesses?
- Negative profit margin.
- High marketing expenses.
- Dependence on prescription approvals.
- Intense competition.
What Could Drive PETS Stock Higher?
- Expansion of online platform and mobile app capabilities to enhance customer experience.
- Potential partnerships with veterinary clinics to expand customer reach.
- Introduction of new private label products to improve profit margins.
- Marketing campaigns to increase brand awareness and customer acquisition.
What Are the Key Risks for PETS?
- Financial-distress signal — its Altman Z-Score of 0.36 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Increasing competition from online and brick-and-mortar retailers.
- Regulatory changes affecting the sale of pet medications.
- Economic downturns impacting consumer spending on pet products.
- Fluctuations in marketing expenses and customer acquisition costs.
What Are the Growth Opportunities for PETS?
- Expansion of Telehealth Services: PetMed Express can leverage telehealth to offer virtual consultations and prescription services, tapping into the growing demand for convenient pet healthcare solutions. The telehealth market is projected to reach $17.4 billion by 2027. By integrating telehealth, PetMed Express can enhance customer engagement and expand its service offerings, potentially increasing revenue and customer loyalty.
- Strategic Partnerships with Veterinary Clinics: Collaborating with veterinary clinics can provide PetMed Express with access to a broader customer base and enhance its credibility. These partnerships can involve offering discounts to clinic clients or integrating PetMed Express's services into the clinic's workflow. This strategy can drive customer acquisition and increase prescription fulfillment rates, contributing to revenue growth.
- Enhancement of Mobile App and Online Platform: Improving the user experience of its mobile app and online platform can drive customer engagement and sales. This includes features such as personalized product recommendations, easy prescription refills, and streamlined checkout processes. A user-friendly platform can attract and retain customers, leading to increased online sales and customer lifetime value.
- Development of Private Label Products: Introducing private label pet medications and supplies can improve profit margins and differentiate PetMed Express from competitors. These products can be offered at competitive prices while maintaining quality, attracting price-sensitive customers and increasing brand loyalty. The private label market is growing, offering PetMed Express an opportunity to enhance profitability and market share.
- Geographic Expansion into Underserved Markets: Expanding into new geographic markets within the United States can drive revenue growth. Identifying regions with high pet ownership rates and limited access to pet pharmacies can provide PetMed Express with a competitive advantage. This expansion can be achieved through targeted marketing campaigns and strategic partnerships with local veterinary clinics and pet organizations.
What Opportunities Does PETS Have?
- Expansion of telehealth services.
- Strategic partnerships with veterinary clinics.
- Development of private label products.
- Geographic expansion.
What Threats Does PETS Face?
- Increasing competition from online retailers.
- Evolving consumer preferences.
- Regulatory changes.
- Economic downturns affecting pet spending.
What Are PETS's Competitive Advantages?
- Established brand recognition with the 1-800-PetMeds brand.
- Direct-to-consumer distribution model.
- Wide range of prescription and non-prescription products.
- Convenient online and mobile shopping experience.
What Does PETS Do?
PetMed Express, Inc., incorporated in 1996 and headquartered in Delray Beach, Florida, operates as a pet pharmacy in the United States. The company markets a wide array of prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. Its product offerings include non-prescription medications and supplies such as flea and tick control, bone and joint care, vitamins, treats, nutritional supplements, and hygiene products. Additionally, it provides prescription medications including heartworm preventatives, arthritis treatments, dermatitis solutions, thyroid medications, diabetes management, pain relief, heart/blood pressure medications, and generic substitutes. PetMed Express sells its products through its Internet website, mobile app, telephone contact center, and direct mail/print, including brochures, postcards, and television advertising under the 1-800-PetMeds and PetMeds brands. The company aims to provide convenient access to pet medications and supplies, catering to pet owners' needs across the United States.
What Products and Services Does PETS Offer?
- Sells prescription and non-prescription pet medications.
- Offers health products and supplies for dogs, cats, and horses.
- Provides flea and tick control products.
- Markets bone and joint care products and vitamins.
- Sells treats and nutritional supplements.
- Offers hygiene products and pet supplies.
- Distributes products through its website, mobile app, and telephone contact center.
- Utilizes direct mail and television advertising for marketing.
How Does PETS Make Money?
- Sells pet medications and supplies directly to consumers.
- Generates revenue through online and offline sales channels.
- Fulfills prescription orders with veterinarian authorization.
- Markets products through advertising and promotional campaigns.
What Industry Does PETS Operate In?
PetMed Express operates within the medical pharmaceutical industry, specifically focusing on pet medications and supplies. The market is characterized by increasing pet ownership and spending on pet health. Competition includes online retailers, brick-and-mortar pet stores, and veterinary clinics. The industry is driven by trends such as pet humanization and the rising demand for specialized pet healthcare products. PetMed Express competes by offering a wide range of products and convenient purchasing options.
Who Are PETS's Key Customers?
- Pet owners seeking convenient access to medications and supplies.
- Owners of dogs, cats, and horses.
- Customers who prefer online and mobile shopping.
- Individuals looking for cost-effective pet healthcare solutions.
Net sellingInsider Activity
Over the past six months, PetMed Express, Inc. insiders filed 2 SEC Form 4 transactions — 1 sales and 1 purchases. On net that is roughly 1K shares disposed (about $44K), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project PetMed Express, Inc. revenue of about $178.5M for fiscal 2026, with EPS near $-2.72.
F-Score 3/9Financial Health
PetMed Express, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.36 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -70.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -86.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.84 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -152.2%, the inverse of the P/E and a quick read on earnings relative to price.
PetMed Express, Inc. (PETS) Valuation Context
Valued at $41.89M, PETS is classified as a micro-cap stock. Relative to its peer group, PETS's quantitative score of 28/100 is below the peer average of 65/100.
PETS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in PETS' future growth, indicating that those closest to the company believe in its potential.
- Community sentiment has turned increasingly positive, with social media discussions highlighting strong brand loyalty among pet owners.
- The company has been expanding its product offerings, which could enhance its market position and attract new customers.
- Recent partnerships in the pet care industry are seen as strategic moves to boost revenue streams and enhance brand visibility.
Bear Case
- Concerns about rising competition in the pet sector may impact PETS' market share, as new entrants are aggressively marketing similar products.
- Some community members express skepticism about the sustainability of recent growth, fearing it may be a short-term trend rather than a long-term strategy.
- Recent supply chain challenges have raised questions about the company's ability to meet demand, potentially affecting customer satisfaction.
- Market sentiment remains cautious due to broader economic uncertainties, which could lead to reduced discretionary spending on pet products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
PETS Latest News
-
BC-Most Active Stocks
Associated Press · Jun 29, 2026
-
PETS Q4 Earnings Call Focuses on Turnaround Foundation
zacks.com · Jun 5, 2026
-
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
benzinga · Jun 3, 2026
-
PetMed Express Inc (PETS) Q4 2026 Earnings Call Highlights: Navigating Challenges and Embracing ...
Yahoo! Finance: PETS News · Jun 3, 2026
PETS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PETS.
Price Targets
Wall Street price target analysis for PETS.
PETS MoonshotScore
What does this score mean?
The MoonshotScore rates PETS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
BC-Most Active Stocks
PETS Q4 Earnings Call Focuses on Turnaround Foundation
12 Consumer Discretionary Stocks Moving In Wednesday's Intraday Session
PetMed Express Inc (PETS) Q4 2026 Earnings Call Highlights: Navigating Challenges and Embracing ...
Leadership: Leslie C. G. Campbell
Chief Executive Officer
Leslie C. G. Campbell serves as the Chief Executive Officer of PetMed Express, Inc. Her background includes experience in managing and leading teams within the retail and healthcare sectors. Campbell's expertise lies in strategic planning, operational efficiency, and customer relationship management. She is responsible for overseeing the company's overall performance and driving its growth initiatives.
Track Record: Under Leslie C. G. Campbell's leadership, PetMed Express, Inc. has focused on enhancing its online platform and expanding its product offerings. She has emphasized improving customer satisfaction and streamlining operations to enhance profitability. Campbell's strategic decisions have aimed to position PetMed Express as a leading provider of pet medications and supplies in the United States.
Common Questions About PETS (Healthcare)
What does PetMed Express, Inc. do?
PetMed Express, Inc. operates as a pet pharmacy, offering a wide range of prescription and non-prescription medications, health products, and supplies for dogs, cats, and horses. The company distributes its products through its website, mobile app, telephone contact center, and direct mail. PetMed Express aims to provide convenient and cost-effective access to pet healthcare products for pet owners across the United States, emphasizing customer service and product availability.
What do analysts say about PETS stock?
Analyst coverage of PetMed Express, Inc. (PETS) is limited, reflecting its small market capitalization. Key valuation metrics include its market cap of $41.89M and negative profit margin of -35.5%. Growth considerations focus on the company's ability to improve profitability, expand its online presence, and compete effectively in the pet medication market. Investors should conduct thorough due diligence and consider the company's financial performance and competitive landscape.
What are the main risks for PETS?
The main risks for PetMed Express, Inc. include increasing competition from online retailers and brick-and-mortar stores, regulatory changes affecting the sale of pet medications, and economic downturns impacting consumer spending on pet products. Additionally, the company faces challenges in managing marketing expenses and customer acquisition costs. These risks could affect PetMed Express's revenue, profitability, and market share.
How does PetMed Express, Inc. navigate regulatory approval processes?
PetMed Express, Inc. operates under the regulatory framework set by the FDA and state pharmacy boards, ensuring compliance with prescription requirements and medication safety standards. The company works closely with veterinarians to verify prescriptions and adheres to labeling and packaging regulations. Maintaining compliance is critical for PetMed Express to continue dispensing prescription medications and avoid penalties or disruptions to its business operations. The company must adapt to evolving regulatory requirements to ensure its continued success.
What are the key growth opportunities for PETS in healthcare?
Key growth opportunities for PetMed Express, Inc. include expanding its telehealth services to offer virtual consultations and prescription services, forming strategic partnerships with veterinary clinics to broaden its customer base, and developing private label products to improve profit margins. Additionally, geographic expansion into underserved markets within the United States can drive revenue growth. These initiatives can position PetMed Express as a leading provider of pet healthcare solutions.
What are the key factors to evaluate for PETS?
PetMed Express, Inc. (PETS) holds an AI score of 28/100 (low). Not financial advice.
How frequently does PETS data refresh on this page?
PETS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PETS's recent stock price performance?
PetMed Express, Inc. (PETS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- Competitive landscape assessment is based on publicly available information.